BCM
DYN icon

Bayesian Capital Management’s Dyne Therapeutics DYN Stock Holding History

Bayesian Capital Management’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-16,400
Closed -$172K – 632
2025
Q1 		$172K Buy
+16,400
New +$235K 0.03% 508

Other funds holding DYN

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bayesian Capital Management's DYN Position: Q2 2025 in Review

Bayesian Capital Management sold out of Dyne Therapeutics (DYN) in Q2 2025, closing a stake of 16,400 shares — an estimated $172K sold.

Bayesian Capital Management first reported a position in DYN in Q1 2025 and held it in 1 quarter. The position peaked at $172K in Q1 2025. 197 funds tracked by Wall St. Rank hold DYN as of Q2 2025.

  • Bayesian Capital Management reported no remaining Dyne Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Bayesian Capital Management sold 16,400 Dyne Therapeutics shares in Q2 2025, an estimated $172K.
  • Bayesian Capital Management first reported a position in Dyne Therapeutics in Q1 2025 and held it in 1 quarter.
  • Bayesian Capital Management's Dyne Therapeutics position peaked at $172K in Q1 2025.
  • 197 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2025.

Based on Bayesian Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.